Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.
Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.
Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.
Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported significant advancements in its clinical pipeline during their year-end 2022 update. Notably, AB-729, an RNAi therapeutic for chronic HBV, is undergoing multiple Phase 2a trials, with preliminary data expected in 2023. The company also plans to initiate Phase 1 trials for oral candidates AB-101 and AB-161, along with AB-343 targeting coronaviruses. Financially, Arbutus ended 2022 with $184.3 million in cash. Total revenue surged to $39 million, primarily from a $26 million license agreement. However, R&D expenses rose to $84.4 million, leading to a net loss of $69.5 million, an improvement over the previous year's loss.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its upcoming fourth quarter and year-end 2022 financial results, scheduled for March 2, 2023. A press release will be issued at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases including Hepatitis B and SARS-CoV-2, with lead compound AB-729 currently in phase 2 trials. Arbutus aims to provide a functional cure for chronic HBV. Investors can access the conference call via a registration link or through the company's website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced participation in three investor conferences: the SVB Securities Global Biopharma Conference from February 14-16, 2023, the Cowen 43rd Annual Health Care Conference with a formal presentation on March 7, and the Jefferies Biotech on the Bay Summit from March 16-17, 2023. The company focuses on developing innovative therapeutics for viral diseases, particularly Hepatitis B and coronaviruses. Its lead compound, AB-729, is currently under evaluation in multiple phase 2 clinical trials. Access to webcasts for the presentations will be available on the Arbutus website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Dr. Tram Tran has resigned from its Board of Directors, effective February 26, 2023, to transition into public service. Dr. Tran, a board member since November 2021, was part of the Executive Compensation and Human Resources Committee, contributing her expertise in virology to the company's hepatitis B and COVID-19 pipeline. The resignation was amicable and not due to any disagreements. The company is initiating a search for a new independent board member to fill her vacancy. Arbutus focuses on developing therapeutics for Hepatitis B and coronaviruses, including its lead candidate, AB-729.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its 2023 objectives, focusing on advancing its HBV assets, AB-101 and AB-161, into Phase 1 clinical trials and expecting data from ongoing AB-729 trials. The company anticipates significant data from multiple Phase 2a trials in 2023 and plans to advance AB-343, a new coronavirus asset, into clinical trials. As of December 31, 2022, Arbutus had approximately $185 million in cash, providing a runway into Q4 2024. The company aims to address unmet needs in HBV and coronavirus treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced promising preliminary data from the lead-in phase of its Phase 2a clinical trial for AB-729, targeting chronic Hepatitis B virus (cHBV). With 43 patients enrolled, the initial results show a 1.51 log decline in HBsAg after 16 weeks, similar to Phase 1b results. The treatment, combined with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a, demonstrates a safe profile. The company expects to release further results from the trial's IFN phase in the first half of 2023, underscoring its commitment to addressing chronic HBV infection.
Arbutus Biopharma Corporation (ABUS) reported strong cash reserves of $190.2 million as of September 30, 2022, sufficient to fund operations into Q2 2024. The company showcased promising data on its RNAi therapeutic AB-729, indicating long-term control of HBV biomarkers. Total revenue increased 79% year-over-year to $6.0 million, driven by collaborations. However, the net loss decreased from $24.2 million to $17.6 million, reflecting a loss per share of $0.12. Despite challenges from COVID-19, the company is on track to achieve milestones in its clinical pipeline by year-end.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 am GMT / 6:30 am EDT. The presentation will be accessible via a live webcast on Arbutus' website, with an archived replay available afterward. Arbutus is focused on developing therapeutics for viral diseases, particularly Hepatitis B and coronaviruses, with key compounds like AB-729 currently in phase 2 clinical trials.
Arbutus Biopharma (ABUS) announced promising findings from clinical trials of its RNAi therapeutic, AB-729, showing sustained HBV suppression in patients up to 44 weeks after treatment cessation. Additionally, preclinical data for AB-101, an oral PD-L1 inhibitor, indicate improved HBV immune response when combined with RNAi therapy. However, the company has halted AB-836 development due to safety concerns. Upcoming poster presentations at the AASLD – The Liver Meeting will detail these findings. A conference call is scheduled for November 4, 2022, to discuss these results.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that it will present three posters with clinical data at the AASLD Liver Meeting 2022 from November 4-8 in Washington, DC. The presentations will cover findings from its lead compound AB-729 and the preclinical PD-L1 inhibitor AB-101. Key data highlights include:
- Long-term HBV control in patients after stopping nucleos(t)ide analogue therapy.
- Increased immune responses in HBV-infected mice with combined treatment.
- Interim analysis of a Phase 2 study showing safety in various treatment combinations.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
